The promyelocytic leukemia (PML) protein, initially discovered as a part of the PML/retinoic acid receptor alpha fusion protein, has been found to be a critical player in oncogenesis and tumor progression. Multiple cellular activities, including DNA repair, alternative lengthening of telomeres, transcriptional control, apoptosis and senescence, are regulated by PML and its featured subcellular structure, the PML nuclear body. In correspondence with its role in many important life processes, PML mediates several complex downstream signaling pathways. The determinant function of PML in tumorigenesis and cancer progression raises the interest in its involvement in cancer stem cells (CSCs), a subpopulation of cancer cells that share properties with stem cells and are critical for tumor propagation. Recently, there are exciting discoveries concerning the requirement of PML in CSC maintenance. Growing evidences strongly suggest a positive role of PML in regulating CSCs in both hematopoietic cancers and solid tumors, whereas the underlying mechanisms may be different and remain elusive. Here we summarize and discuss the PML-mediated signaling pathways in cancers and their potential roles in regulating CSCs.
INTRODUCTION
The promyelocytic leukemia (PML) protein (also known as Myl or TRIM19) was originally identified as a part of the PML/retinoic acid receptor alpha (RARa) fusion protein, which is generated from the t(15;17) genomic translocation-derived PML/RARa fusion gene. [1] [2] [3] The PML/RARa fusion protein has been demonstrated to have a critical role in the development of acute promyelocytic leukemia (APL) and targeting PML/RARa with chemicals such as retinoic acid (RA) and/or arsenic trioxide (As 2 O 3 ) has shown substantial therapeutic effect on this lethal cancer. 4 Although most studies of PML/RARa fusion protein focused on APL, PML itself has been found to be a pivotal player in a variety of cellular processes, including proliferation, differentiation, DNA repair, apoptosis and senescence, in either cancer or normal cells. There are numerous reports describing PML as a tumor suppressor, with respect to its function in mediating programmed cell death. However, when it comes to the tumor-initiating cells or cancer stem cells (CSCs), there seems to be another scenario. Several studies have implied the involvement of PML in the maintenance of 'stemness' in different type of stem cells. The most overwhelming evidences came from the recent studies demonstrating the critical role of PML in hematopoietic stem cells (HSCs) and leukemia stem cells. PML was found to be highly expressed in most chronic myeloid leukemia (CML) and targeting PML eradicated quiescent leukemia-initiating cells (LICs). 5 The role of PML in the maintenance of stem cells is not limited to the pathological conditions but also applies to normal HSCs. 6 PML is able to control HSC asymmetric division by regulation of the peroxisome proliferator-activated receptor d (PPAR-d)-fatty acid oxidation (FAO) pathway, suggesting a metabolic mechanism utilized by PML in regulating stem cells. 6 These reports as well as other studies in solid tumors strongly suggest that PML-mediated signaling pathways have important roles in CSCs and tumor progression.
PML PROTEIN STRUCTURE AND ISOFORMS
PML is a member of the tripartite motif (TRIM)-containing protein superfamily. Similar to other members of TRIM family, all PML isoforms contain a conserved TRIM motif that comprises a RING domain, two B-box domains and a coiled-coil domain. 7, 8 Most PML isoforms also have a nuclear localization signal, thus show a predominant nuclear localization. In addition, most PML isoforms contain three well-characterized small ubiquitin-related modifier (SUMO)-1 modification sites (at position 65 in the RING domain, 160 in the B1-Box and 490 in the nuclear localization signal) 7, 9 ( Figure 1 ). There are seven main isoforms of PML generated by alternative usage of the 3 0 -end exons. However, evidences suggested that all these isoforms have a/b/c variants due to alternative splicing of exons at 3 0 -end. 10, 11 Noticeably, nomenclature of PML isoforms differs in some publications. For example, PML 3 is identical to PML IV in different reports. 7 It will be important to determine the differential role of different PML isoforms in various cellular activities.
THE REGULATION OF PML BY VARIOUS MECHANISMS Transcriptional and translational regulations
In accordance with the complex regulation mechanisms mediated by PML, the regulation of PML protein amount in cells occurs at different levels. Several studies have shown that the transcription of PML is tightly controlled. Interferon (IFN) stimulation rapidly upregulates PML transcription in normal and APL cells, likely via the signal transducers and activators of transcription (STATs) and IFN regulatory factor 3 (IRF3). [12] [13] [14] [15] Correspondingly, PML promoter contains an IFN-a/-b-stimulated response element as well as an IFN-g activation site serving as binding sites for IFN-responsive transcriptional factors. 14, 15 In addition, PML is a direct transcriptional target of p53 and several p53 responsive elements have been found in the PML promoter region. 16, 17 p73, a homolog of p53, cooperates with its co-activator Yes-associated protein to activate PML transcription, whereas Akt/protein kinase B negatively regulates such activation. 17 Besides, PML transcription is under the control of the janus kinase/STAT pathway in responsive to several stimuli. 18, 19 Moreover, translation of PML protein is enhanced by oncogene Ras through the Ras/MEK1 (mitogen-activated protein kinase/extracellular signal-regulated kinase 1)/mammalian target of rapamycin (mTOR)/eukaryotic initiation factor 4E (eIF4E) pathway. 20, 21 Besides these presynthesis regulatory mechanisms, the regulation of PML protein levels by other modifications is much more complex. Sumoylation PML is the most well-known protein that can be covalently modified by Sumo, a small ubiquitin-like protein. Sumo-1 modification was initially discovered in the PML component of the PML/RARa fusion protein, 22 and soon it was found that PML itself can be modified by Sumo-1, as well as Sumo-2 and Sumo-3. 23, 24 Depletion of Sumo-3 markedly reduced the number of PML-containing nuclear bodies (NBs) and their integrity, which was rescued by exogenous expression of Sumo-3 but not Sumo-1, suggesting distinct roles of Sumo-1 and Sumo-3 in PML NB formation. 25 Meanwhile, it was thought that poly-sumoylation chains may be dominantly composed of Sumo-2/3 by a conserved lysine (Lys 11) embedded in a consensus modification site 26 and that Sumo-1 may be linked to the end of a poly-Sumo-2/3 chain, effectively terminating chain growth. 27 On the other hand, several sentrin-specific peptidases (SENPs) had been reported to specifically cleave Sumo-2/3 from PML proteins. These facts strongly indicated differential roles of Sumo-1 and Sumo-2/3 on PML. Systematic mutational analysis revealed K65, K160 and K490 as the key sumoylation sites in PML. 28 Ubc9, a ubiquitinconjugating enzyme, functions as the Sumo E2 ligase that interacts with PML and is the main upstream enzyme executing conjugation of Sumo-1 to PML. 29, 30 Although in vitro studies suggested that Sumo modification may be catalyzed by two enzymes and that Ubc9 has full capacity to conjugate Sumo to PML, recent reports discovered a Sumo E3-ligase PIAS1 that is also responsible for PML sumoylation. 31, 32 The PML oligomerization, which can be induced by direct interaction with As 2 O 3 , is the key step for interaction between PML and Ubc9. 33 Sumoylation has been proved to be a dynamic process. A family of protease, namely the sumo1/sentrin specific peptidase (SENP), is responsible for removing the sumo from proteins. Among them, SENP1 and SENP2 process de-conjugation of sumo-1, while SENP3, 5 and 6 prefer sumo-2 and sumo-3 as their substrates. [34] [35] [36] [37] The distinct sets of SENPs for Sumo-1 and Sumo-2/3 indicated different roles of these Sumo modifications on PML functions. As a prerequisite for PML NB formation and the interaction with sumo-interacting motif in partner proteins, sumoylation endows PML with the capacity to be a platform to mediate several signaling events, which are discussed in detail in other paragraphs. However, sumoylation can dichotomically regulate PML protein levels either by triggering the ubiquitination-mediated degradation 38, 39 or preventing PML from the phosphorylation-induced degradation. 40 Ubiquitination Ubiquitination of PML was reported to mediate its degradation, and such post-translational modification was found to be promoted by direct phosphorylation at Ser517 by Casein kinase 2 (CK2). 41 Other studies showed that Ubc9-mediated sumoylation could trigger polyubiquitination and proteasome-dependent degradation of PML. After As 2 O 3 stimulation, PML-linked Sumo recruits a E3-ligase RNF4, which, in turn, adds ubiquitin to Lys48 in PML. 38, 42, 43 However, the sumoylation dependent recruitment of RNF4 is independent of CK2-induced serine phosphorylation. 39 Interestingly, sumoylation of PML by PIAS1 promotes CK2 interaction along with the ubiquitination-mediated degradation of PML. 32 Thus, the role of CK2-induced phosphorylation in PML ubiquitination and degradation remains to be unveiled. In addition to RNF4, other E3 ligases also participate in PML ubiquitination. A mammalian E3-ligase human papillomavirusE6-associated protein promotes PML ubiquitination and degradation, thus preventing PML-induced senescence in Myc-induced B-cell lymphomagenesis. 44, 45 The ubiquitin-like with PHD and RING finger domain 1 is another E3 ligase that mediates PML ubiquitination in endothelial and cancer cells. 46 Alternatively, a Cullin3-KLHL20 ubiquitin ligase-dependent pathway is involved in the hypoxia-induced PML degradation. 47 Other modifications Other post-translational modifications occur in PML but they usually function to regulate sumoylation or/and ubiquitination. After As 2 O 3 stimulation, mitogen-activated protein kinase (MAPK) phosphorylates PML, which, in turn, increases sumoylation of PML and promoted PML-mediated apoptosis. 48 PML can be acetylated and the increased acetylation associates with enhanced sumoylation. Although the enzyme responsible for PML acetylation remains unknown, the histone deacetylase (HDAC) may have an essential role in deacetylation of PML. 49 In addition, PML stability is regulated by the peptidyl-prolyl cis-trans isomerase Pin1. Although the detailed mechanism is poorly understood, the phosphorylation-dependent binding of PML to Pin1 results in degradation of PML protein, which is antagonized by sumoylation. 40, 47, 50 Thus, functional regulation of PML by multiple modifications is a complex network ( Figure 2 ).
PML NBS
The formation of PML NBs is a critical event for PML to mediate important signaling pathways. PML NBs or oncogenic domains are concentrated protein structures displayed as spheres of 0.1-1.0 mm in diameters. 51 Initially observed in APL cells, 52, 53 PML NBs are present in most cell lines and many tissues. Besides PML protein, some other proteins such as sp100 and CREB-binding protein (CBP) are always harbored in the PML NBs. 12, 54 But PML is the fundamental and central organizer of PML NBs. Several elements of PML protein can regulate the formation of NBs. The N-terminal part of PML protein containing the RING, B1-B2 and coiled-coil domains is indispensable and sufficient to target PML proteins to the NBs, 55 while the C-terminal regions of PML isoform II and IV can form NBs independently. 56 The most important regulation of PML NB integrity comes from sumoylation. Knockdown and overexpression experiments suggested that both Sumo-1 and Sumo-3 are essential for the NB formation and stabilization,. 25, [57] [58] [59] In addition, the RING domain is required for efficient PML sumoylation, 60 and mutation of certain residues in the RING domain results in fewer but larger PML NBs. 61 Independent of PML sumoylation, a sumo-binding motif located in the C-terminal of PML targets PML proteins to NBs by interaction with sumoylated proteins, including PML itself in the NBs. 60 PML NBs are involved in several aspects of cellular activities. PML interacts with a DNA helicase called the bloom syndrome protein (BLM) in NBs, indicating a role of PML in the maintenance of genomic stability. 62 Newly synthesized RNA is associated with the periphery of PML NBs, suggesting the contribution of these NBs to the transcriptional control of certain genes. 63 The association of PML NBs with transcriptionally active genomic regions further supports the role of PML NBs in regulating gene transcription. 64 As huge complexes comprising multiple key components of various signaling pathways, PML NBs participate in DNA repair, cell apoptosis, senescence and other cellular processes via recruitment of different signaling molecules.
REGULATION OF CSCS BY PML
As PML has been shown to be involved in the promotion of cell apoptosis and senescence, PML was widely recognized as a tumor suppressor. Several attempts have been made to restore PML expression or the NB formation in order to eliminate cancer cells by promoting cell death. However, early studies on PML showed that the PML-RARa fusion protein can inhibit differentiation and promote survival of myeloid precursor cells. [65] [66] [67] Degradation of PML-RARa by RA and As 2 O 3 treatment eliminates LICs in mouse APL. 68 These facts indicate a positive role of PML-RARa in maintaining CSCs in leukemia. But the role of PML protein itself in CSCs remained unknown until recently. The breakthrough regarding the role of PML in CSCs came from the study in CML. 5 PML was found to be highly expressed in most CML chronic phase samples from patients. CML patients with lower PML expression displayed favorable clinical outcome and better overall survival, suggesting a positive correlation between PML level and CML malignancy. Consistently, HSCs also highly express PML, accompanied by increased numbers of PML NBs relative to the committed cells. 5 C-Kit þ Sca-1 þ Lin À (KSL) stem cells isolated from PML knockout mice showed impaired colony formation when cultured in vitro. 5 In hematopoietic reconstitution, the percentage of Pml À / À KSL stem cells significantly decreased 16 weeks after transplantation, suggesting that PML acts to maintain normal HSCs. 5, 6 Likewise, Pml-null LICs showed remarkable reduction in survival, indicating the positive role of PML in LIC maintenance. 5 As increased activity of mTOR was observed in the Pml À / À HSCs, and the mTOR inhibitor rapamycin substantially rescued the effect of PML deletion, it has been suggested that PML exerted its function in LICs by repression of mTOR activity. Notably, targeting PML in these experiments eradicated quiescent but not all LICs, suggesting PML may be required for a tight control of stem cell cycling to prevent stem cells from exhaustion. However, the detailed mechanism utilized by PML to maintain stemness in HSCs and hematopoietic CSCs remained elusive. 5 A potential link between PML and HSC maintenance is PPAR-d, as PPAR-d agonists rescued the defective Pml À / À HSCs and that Pml loss resulted in PPAR-d dependent loss of asymmetric division. 6 PPAR-d is expressed in KSL stem cells and deletion of Ppard gene markedly affected long-term repopulation of KSL cells. 6 Consistently, treatment of mice with the PPAR-d activator increased the capacity of long-term culture initiating cell from the bone marrow cells. 6 Along with other experiments in vitro and in vivo, activation of PPAR-d did enhance HSC function. PPAR-d has crucial roles in sensing fatty acids and the activation of the FAO transcriptional program. FAO is detected in HSCs but not in differentiated cells, and inhibition of mitochondrial FAO led to a significant reduction in the number of HSCs in the bone marrow. 6 Meanwhile, the FAO inhibitor prevents the beneficial effect of PPAR-d activator on HSC. 6 These facts put FAO in the downstream of PPAR-d in the regulation of HSC maintenance. These studies support a positive role of PML in CSC maintenance. 6 In fact, such mechanism is not limited to hematopoietic cancers but also solid tumors. It has been found that PML is overexpressed in a subset of breast cancers and enriched in triple-negative cases, the most malignant subtype that may be due to CSCs. 69 PML expression in the breast cancer correlated with poor prognosis, rapid recurrence and the activation of PPAR-d signaling. 69 Similar to the situation in HSCs, PML regulates PPAR-d-FAO pathway to promote cell survival in breast cancer cells. 69 These studies unveiled a prosurvival effect of PML on cancer cells, particularly CSCs. However, the molecular mechanisms remain poorly understood.
POTENTIAL ROLES OF PML IN STEM CELL MAINTENANCE
Growing evidences have supported the involvement of PML in regulating stem cell properties. In mouse embryonic stem cells, Oct3/4 has been found to be expressed preferentially adjacent to PML NBs. 70 The orphan nuclear receptor Tr2 that functions as an upstream activator of Oct4 is also localized to the PML NBs. 71 In this scenario, PML may have a role in partitioning and activating Tr2. 71, 72 Oct4, as well as other key transcriptional factors for stem cell maintenance, including Myc, Nanog, Stat3 and REST, are associated with PML in a repression complex in stem cells, [73] [74] [75] [76] although the functions of such interactions remain unclear. In addition, it has been demonstrated that PML helps to maintain an open chromatin conformation of the Oct4 promoter region for its constant expression in stem cells. 77 These observations imply that PML has a role in regulating the expression of key stem cellspecific transcriptional factors. Interestingly, PML NBs in stem cells appear different from that in differentiated cells. There are fewer but larger PML NBs in human embryonic stem cells that lack SUMO-1, sp100 or Daxx. 78 However, the functional significance of the altered PML NB structure is not clear.
The direct evidences of PML impact on stem cells came from studies on development. During pregnancy-induced development of mammary secretory epithelium, PML expression is tightly controlled by Stat family of transcriptional factors. Deletion of PML gene in mice results in aberrant differentiation of mammary epithelia with reduced ductal and alveolar development, which may arise from the disturbed balance of two distinct luminal progenitor populations. 79 During nervous system development, PML expression is restricted to neural progenitor cells in the developing cortex. PML knock out in mice increases the overall number of neural progenitor cells but impairs the transition between the two major progenitor types, radial glial cells and basal progenitors, which results in a reduction of cell differentiation and a decrease in thickness of the cortex wall. 80 Although the detailed mechanisms underlying these phenotypes are not clear, these observations undoubtedly imply an important role of PML in regulating cell stemness in normal development.
PML-MEDIATED SIGNALING PATHWAYS IN CELLULAR ACTIVITIES
PML and DNA repair One of the most important cellular processes regulated by PML is DNA repair. The hMre11/Rad50/NBS1 repair complex, involved in the repair of DNA double-strand breaks, is colocalized at PML NBs after radiation. 81, 82 The BLM/Rad51/RPA (replication protein A) repair complex, along with PML, form foci at sites of singlestranded DNA in response to radiation. 83 In addition, PML colocalizes with the DNA damage response protein TopBP1 to stabilize this protein and forms a huge repair complex containing Rad50, Brca1, ATM (ataxia telangiectasia mutated), Rad9 and BLM. 84 After radiation, RPA is released from PML NBs to the putative DNA damage sites and helps DNA repair. Translocation of RPA is regulated by the checkpoint kinase ATR, 85 or else RPA is transported by hRIPbeta (human RPA-interacting protein alpha). 86 Confocal real-time imaging suggests that PML NBs are predetermined processing sites for damaged DNA after ultraviolet radiation. 87 The number of PML NBs associated with radiationinduced DNA damage is under the control of NBS1, ATM, Chk2 and ATR. 88 Moreover, there are evidences indicating that PML NBs support homologous recombinational repair of chromosomal DNA double-strand breaks. 89 In general, PML serves as a sensor of DNA damage as well as an organizer of DNA repair complexes. Thus, PML has important roles in facilitating DNA repair to maintain genomic stability and integrity.
PML-mediated alternative lengthening of telomeres (ALT)
The immortalized human cells without telomerase usually maintain their telomeres by a mechanism known as ALT. Increasing evidences suggest that ALT may be involved in CSC maintenance. 90 PML has an important role in regulating ALT in cancer cells. In fact, ALT cells contain a novel PML body called ALTassociated PML body (APB). APBs comprise PML, telomeric DNA, the telomeric repeat binding factor 1 or 2 (TRF1/2) and proteins involved in DNA synthesis and recombination, such as NBS1, Mre11, Rad51 and Rad52. 82, 91, 92 The proteins related to DNA synthesis are recruited to pre-assembled APBs. 93 Given the similarity between APB recruited protein complex and the DNA repair complex, it is not surprising to discover the involvement of ALT in response to DNA damage stimuli. APBs may recognize and process telomeric DNA as double-strand breaks. [94] [95] [96] Reciprocally, telomeric DNA could mediate de novo PML NB formation. 97 Some factors may help telomeric DNA to promote PML NB nucleation. For instance, nucleostemin promotes the recruitment of PML IV to sumoylated TRF1 and thus prevents telomere damage, while depletion of nucleostemin reduces the number of APBs. 98 Interestingly, although APBs are regarded as a feature of ALT cells, recent study suggests that similar mechanisms operate in non-neoplastic cells, possibly activated by DNA damage. 99 These studies indicate that PML has a crucial role in cancer cell immortalization by promoting ALT.
PML and transcriptional control PML NBs have been proposed as hot spots for transcriptional regulation. Existence of nascent RNA polymerase II transcripts within PML NBs has been demonstrated. 54 Several reports have shown the cooperation between PML NBs and transcriptional factors or cofactors to regulate transcription of certain target genes. [94] [95] [96] [97] [98] PML directly interacts with Sp1 and disrupts its binding to DNA, thereby inhibits its transactivation of epidermal growth factor receptor promoter. 100 PML also forms complex with pRb and abolishes the activation of gluococorticoid receptorregulated transcription by pRb. 101 In addition, PML is required for the tumor-suppressor Mad-mediated transcriptional repression by interaction with a series of corepressors, such as c-Ski, N-CoR and mSin3A. 102 Importantly, PML represses nuclear factor-kB-induced transcription of A20 by competitively binding to A20 promoter. 103 Moreover, PML interacts with an orphan receptor Nur77, interferes with Nur77 DNA binding and inhibits transactivation of downstream target genes. 104 PML functions not only as a repressor but also as an activator of transcription. PML NBs are associated with transcriptionally active genomic regions. 64 PML is able to interact with Ap-1 and stimulates its transcriptional activity. 105 In the RA pathway, PML is required for the RA-dependent transactivation of the p21WAF1/CIP1 gene. 67 In addition, PML releases transcription of Daxx-target genes such as Pax3 by sequestering Daxx in NBs. 106, 107 PML also interacts with b-catenin and transactivates a subset of b-catenin-responsive genes, including the tumor suppressor alternative reading frame product (ARF) but not cyclin D1. 108 Upon ultraviolet irradiation, PML associates with c-Jun to promotes its transcriptional activity. 109 Other than recruitment of cofactors, PML can promote transcription by stabilizing the transcriptional factor complex. For example, PML protects homeodomain-interacting protein kinase 2 and CBP from ubiquitination-mediated degradation, thus activating p53-induced transcription. 110 Similarly, PML promotes major histocompatibility complex class II gene expression by preventing the class II transactivator from proteasomal degradation. 111 In summary, PML can be either a negative or a positive regulator of gene transcription depending on its interacting cofactors.
PML-mediated epigenetic control Epigenetic control and the consequent regulation of gene expression attract enormous attention in cancer and stem cell research. Although there is no direct evidence for the involvement of PML in epigenetic regulation, it has been demonstrated that PML-mediated transcriptional repression is dependent on its interaction with HDAC. 112 Trichostatin A, a specific inhibitor of HDAC, inhibits the transcriptional repressive effect of PML. 112 Despite the main function of HDAC to promote sumoylation of PML, it is likely that histones localized in PML NBs may be substrates of HDAC. Meanwhile, a histone H3 lysine 9 (H3K9)-specific methyltransferase Setdb1 also localizes at PML NBs and physically interacts with PML. Setdb1 binds to the promoter of Id2 and suppresses its expression by installing H3K9 methylation, indicating an epigenetic mechanism regulated by PML to repress transcription. 113 It may be highly interesting to determine the role of PML in epigenetic regulation in normal and CSCs.
PML and the regulation of apoptosis Although PML has a critical role in stem cell maintenance, PML has been shown to be essential for the regulation of multiple apoptotic pathways. PML is required for the Fas-, tumor necrosis factor (TNF)-, IFN-and ionizing radiation-induced Caspase-3 activation, and knock out of PML protects the cells from apoptosis. 114 Meanwhile, PML also contributes to the apoptosis independent of caspase-3 activation, potentially by recruiting BAX and p27KIP1 into NBs. 115 PML NBs are able to recruit the TNFR1-associated death domain to induce a caspase-independent apoptosis. 116 Interestingly, Chk2 kinase autophosphorylation in response to irradiation is mediated by interaction with PML and the activated Chk2 is essential for the p53-independent ATM-Chk2 apoptotic pathway. 117, 118 Moreover, cytoplasmic PML is an essential modulator for the transforming growth factor-b-induced apoptosis by physically interacting with transforming growth factor-b signaling proteins Smad2 and Smad3. 119 Alternatively, PML can sensitize TNF-a-induced apoptosis by inhibiting the nuclear factor-kB survival pathway. 120 Likewise, PML is able to promote the Fas-induced apoptosis by interacting with p38 MAPK, sequestering it from upstream MKKs, thus blocking activation of p38 MAPK. 121 In addition, PML promotes transcription of TNF-related apoptosis-inducing ligand and thus mediates IFN-a-induced apoptosis in myeloma. 122, 123 Post-translational modifications of PML have important impact on its role in apoptosis. Sumoylation of PML contributes to the resistance against the Fas-induced cell apoptosis by blocking Daxx in NBs. 124 However, phosphorylation of PML results in retention of the inhibitor-kB kinase e kinase in PML NBs, thereby contributing to protection against DNA-damage-induced apoptosis. 125 PML has a critical role in regulating the p53-mediated apoptosis. P53 is recruited to PML NBs by interaction with PML. DNAdamage-induced apoptosis as well as p53-mediated transcriptional activation are impaired in PML-deficient cells. [126] [127] [128] [129] Furthermore, PML is required for the gain of function by mutant p53. 130 These facts strongly demonstrate the pivotal role of PML in mediating p53 functions. Functional p53 requires acetylation at lysine 382 by CBP, which occurs within PML NBs. 129, [131] [132] [133] In addition, PML and p53 form a ternary complex with the key Wnt signaling regulator AXIN. PML and AXIN rely on each other to phosphorylate and activate p53. 134 On the other side, the deacetylase SIRT1 is recruited to PML NBs where it deacetylates p53 and represses the p53-mediated transactivation. 135 Moreover, PML can activate p53 by inhibition of Mdm2 (HDM2 in human). PML recruits Chk2 and p53, resulting in phosphorylation of p53 at serine 20 by Chk2, which, in turn, prevents p53 from Mdm2-mediated ubiquitination and degradation. 136 Alternatively, PML competes with Mdm2 for binding to p53, thus antagonizes the inhibitory effect of Mdm2 on p53. 137 Furthermore, PML activates p53 by sequestering Mdm2 to the nucleolus. 138 Conversely, Mdm2 can interact with PML and suppress its activity by causing redistribution of PML from nucleolus to cytoplasm. 139 PML-Mdm2 interaction can be disrupted by the activated big MAP kinase 1, resulting in the release of Mdm2 and suppression of p53 activity. 140 Taken together, PML activates p53 either by promoting its phosphorylation and acetylation or by inhibiting its degradation by Mdm2.
PML can also mediate apoptosis via inhibition of the survival kinase Akt/protein kinase B. PML recruits activated pAkt as well as protein phosphatase 2a (PP2a) into NBs, wherein PP2a represses Akt activity by removing the phosphor-modification of Akt in a PML-dependent manner. 141 In addition, PML negatively regulates the eIF4E thus suppressing Akt activation and apoptotic rescue. 142 On the other hand, PML can regulate the lipid phosphatase PTEN (phosphatase and tensin homolog), a suppressor for PI3K/Akt activation, by HAUSP (the herpesvirus-associated ubiquitinspecific protease) deubiquitinase-mediated PTEN stabilization and nuclear-cytoplasmic partitioning. 143 Moreover, extranuclear PML is essential for the Akt-and PP2a-dependent modulation of IP3R phosphorylation and the resultant release of Ca 2 þ from endoplastic reticulum, which, in turn, triggers cell apoptosis. 144 Another key proapoptotic factor regulated by PML is the death domain-associated protein (Daxx). Localization of Daxx to PML NBs is critical for its proapoptotic activity in response to Fas stimulation. 145, 146 Daxx is recruited to NBs by binding to sumoylated PML via its sumo-interacting motif, which, in turn, relieves its transcriptional repressive activity. 35, 58, 106, 107, 147, 148 However, Daxx may exert its proapoptotic activity by repression of some anti-apoptotic genes regulated by nuclear factor-kB. 149 Thus, PML-Daxx interaction has either proapoptotic or antiapoptotic effects, depending on the concrete cellular context. Interaction between PML and Daxx can be regulated by other factors such as zipper-interacting protein kinase, whose kinase activity is required for Daxx localization in PML NBs. 150 PML-mediated senescence Cell senescence is another cell death mechanism regulated by PML. PML can be induced by oncogenic Ras, resulting in increase in both size and number of PML NBs, along with premature cell senescence. 21, 129, 151 PML I and PML IV appear to be the key isoforms for mediating senescence, while the role of other PML isoforms remains unknown. 152, 153 Although the intact PML NB is not required for senescence, PML is necessary but not sufficient to induce senescence. 153 Actually PML promotes the Ras-induced senescence by interaction with p53 and pRb. 21, 151, 129 Deacetylation and repression of p53 by SIRT1 rescues the PMLinduced senescence. 135 Likewise, the melanoma antigen genes A2 (MageA2) interferes with p53 acetylation at PML NBs and thus antagonizes senescence. 154 By contrast, MORC3 helps p53 localization at PML NBs and promotes cellular senescence. 155 Interestingly, in human fibroblasts, pRb, but not p53, seems to be the predominant mediator of PML-induced senescence. 156, 157 In addition, other factors also contribute to PML-mediated senescence. A chromatin regulator HIRA colocalizes with heterochromatin protein HP1 in PML NBs, wherein it interacts with another chromatin regulator ASF1a, resulting in formation of senescence-associated heterochromatic foci and repression of proliferation-associated genes, thereby promoting senescence. [158] [159] [160] Furthermore, PML can be recruited to the promoter region of a T-box PML and cancer stem cells W Zhou and S Bao transcription factor TBX2 by the p130/E2F4 repressor complex, thus inactivating transcription of TBX2 and inducing senescence. Reciprocally, TBX2 protein interacts with PML and antagonizes its pro-senescence function. 161 PML may also utilize other E2Fs in a Rb-dependent manner to trigger cell-cycle exit and senescence. 162 These studies suggest that PML may have opposite roles in different cell types.
CONCLUDING REMARKS
At the first glance, people may be surprised by the complexity and diversity of the signaling pathways regulated by PML. However, a basic fact is that PML has to exert its function and influence on various pathways by its interacting partners. Numerous proteins have been reported to directly interact with PML or indirectly associate with PML through the NBs. PML protein partners can be categorized into five subsets: (1) transcriptional factors/cofactors, such as p53, Daxx and CBP; (2) ubiquitinase/deubiquitinase, such as RNF4 and HAUSP; (3) kinase/phosphatase, such as Akt and PTEN; (4) sumo ligase/sumo1 specific peptidase, such as Ubc9 and SENPs; and (5) deacetylase, such as HDAC. These partners are often under the control of post-translational modifications, including sumoylation, phosphorylation, acetylation and ubiquitination. As the recruitment of partners by PML could be very dynamic in various cell types or in different conditions, it is not too surprising that PML can exert distinct functions in various cellular activities through different partners ( Figure 3 ). PML is not only an adaptor, but more importantly, it functions as an organizer of a much larger platform, namely PML NB. Many signaling factors have been found in PML NBs. They are recruited into PML NBs to approach their substrates, or alternatively, they are translocated to the NBs for accessing their upstream enzymes. In addition, the localization to PML NBs may serve as a sequestering mechanism to regulate the function of the associated proteins in several cases.
As the organizer of this extremely important nuclear structure, PML expression and modification has direct impact on the integrity of PML NBs. Therefore, the complexity and diversity of PML-mediated signaling is further amplified through NBs. Although PML is known as a tumor suppressor in promoting multiple apoptotic pathways, PML does act as an anti-apoptotic factor in certain pathways. PML is involved in DNA repair mechanisms that help cell survival, while PML is also required for the DNA-damage-induced apoptosis. Therefore, we should be very cautious to interpret the tumor-related function of PML under different circumstances.
CSCs have the ability to give rise to the whole heterogeneous populations in the tumor bulk and contribute to therapeutic resistance, tumor angiogenesis, cancer invasion and tumor recurrence after treatments. 163, 164 Thus, targeting CSCs may be critical to improve cancer treatment. As a multi-faceted signal transducer, PML has crucial functions in CSCs. Recent studies on leukemia stem cells suggest that PML is a positive regulator in the maintenance of CSCs. Moreover, PML NBs are observed in glioblastoma stem cells (GSCs). We detected a dramatic change in the size and number of PML NBs during GSC differentiation (Figure 4) , indicating a role of PML in GSC maintenance. The exact role of PML in regulating CSCs requires further investigation. However, the recent discovery suggests that targeting cancers by boosting PML levels may have complicated consequences, as PML may promote the maintenance of CSC population.
